프로팽 바이오파마PPCB 주가

Which stocks are moving before the opening bell on Tuesday?

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, forecasts new medical breakthroughs in the fight against pancreatic cancer over the next decade. Rece

Propanc Biopharma To File CTA In Australia For Phase 1b Study In 30–40 Advanced Cancer Patients; Plans Two Phase 2 Studies In Pancreatic And Ovarian Cancers With 60 Patients Each

The Company plans to file a Clinical Trial Application (CTA) in Australia for a Phase 1b, First-In-Human, Maximum Tolerated Dose study in 30 – 40 advanced cancer patients suffering from solid tumors using PRP in an I.V.

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics ProductionMELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a Contract and Development Manufacturing Organization (CDMO) has been engaged for the GMP manufactur

Propanc Biopharma Engages Manufacturer For Its Lead Asset PRP Ahead Of The Upcoming Phase 1b, First-in-Human Study In 30-40 Advanced Cancer Patients Suffering From Solid Tumors

Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production (plasmid DNA and recombinant proteins) providing services of cell

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic DiseasesMELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported third quarter fina

Propanc Biopharma Q3 EPS $(0.28) Up From $(12.50) YoY

Propanc Biopharma (NASDAQ:PPCB) reported quarterly losses of $(0.28) per share. This is a 97.76 percent increase over losses of $(12.50) per share from the same period last year.

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”). The Reverse Stock S

[10-Q] 분기 실적 — 10-Q

[EFFECT] EFFECT